about
Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubismMonoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?A renaissance for SRCSequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells.Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.Peptide aptamers: recent developments for cancer therapy.Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypesA COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.Genome-wide DNA methylome analysis reveals epigenetically dysregulated non-coding RNAs in human breast cancer.Risk factors for distant metastasis as a primary site of treatment failure in early-stage breast cancer.Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells.Tyrosine Phosphorylation of Caspase-8 Abrogates Its Apoptotic Activity and Promotes Activation of c-SrcNLK functions to maintain proliferation and stemness of NSCLC and is a target of metforminCell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cellsEmerging therapeutic targets in metastatic progression: A focus on breast cancer.Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?Recombinant IgE antibody engineering to target EGFR.(1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration.Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells.Involvement of Src in the Adaptation of Cancer Cells under Microenvironmental Stresses.Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts.
P2860
Q24299210-DD03C1B6-861F-4ECC-A75F-E13B075F2E53Q24542471-A7CD68AD-BFC3-4C8C-9642-B27BA70C7309Q30014833-9A979497-C076-46EB-B0CC-5A89D2D9F98FQ30958440-4FA58C11-0FF6-429C-B78F-D62BCA34D97AQ30997919-DDBFB2D9-0E9B-4BB7-BDEA-14F0F59FF45AQ33216999-86053DC7-3C16-40CC-8552-E9DD376DCC78Q33608593-0891F5AD-9D7C-452A-AA14-F309869A3FADQ34197523-D92321BB-9516-45B8-A304-CDE16FF3D6C1Q34253693-1C2EEB5A-2D11-4AFF-B8AB-0DD3B2E6D4FCQ34465725-CBA629A8-5E56-41FD-B4E6-7D11BD7F6B79Q34774308-D2E79C4E-0764-4743-9FF7-9AB7FA67D990Q35728456-10467E19-AE99-47A3-8D9E-C2225FB8A389Q35996145-26390A0B-E6E0-4546-A3C4-6988C4788A4EQ36206338-557DE1D1-B9CD-4E39-85CD-10EFE24E480FQ36497235-2209DA47-0ED4-498C-A3FC-04E44FACF237Q36854062-55D40FE7-38E4-462A-B588-8715A7E4ECECQ37362042-F3316047-423A-4F5B-8ACC-8B8137333667Q38016758-17076B35-56DE-4F8A-A1E5-849A3DF93804Q38737669-CC84ABF2-D7A7-4C48-8C8B-C0F91FDBB0F3Q39096429-932A1BB0-4BC2-4DE1-9F83-6AD2E4522263Q40423784-DA7D4492-B733-4659-BC19-C6FC50576C96Q42324840-03D5E540-8C2A-498E-A461-41FD1E362F26Q42373819-60B98B6B-5FFA-46CB-BB06-3BA34CA0F4CAQ50128937-1275311D-3E64-40DB-9BEF-654176E25172
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tyrosine kinase signalling in breast cancer
@ast
Tyrosine kinase signalling in breast cancer
@en
Tyrosine kinase signalling in breast cancer
@nl
type
label
Tyrosine kinase signalling in breast cancer
@ast
Tyrosine kinase signalling in breast cancer
@en
Tyrosine kinase signalling in breast cancer
@nl
prefLabel
Tyrosine kinase signalling in breast cancer
@ast
Tyrosine kinase signalling in breast cancer
@en
Tyrosine kinase signalling in breast cancer
@nl
P2860
P921
P3181
P356
P1476
Tyrosine kinase signalling in breast cancer
@en
P2093
P2860
P2888
P3181
P356
10.1186/BCR48
P407
P577
2000-04-17T00:00:00Z
P5875
P6179
1050232165